Regeneron, Sanofi: Dupixent Hits Main Endpoints in Prurigo Nodularis Trial
22 October 2021 - 9:39PM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said a
Phase 3 study of their blockbuster eczema drug Dupixent in the
chronic skin condition prurigo nodularis met its primary and all
secondary endpoints.
The companies said Dupixent significantly reduced itch at 12
weeks, while nearly three times as many Dupixent patients
experienced reductions in both itch and skin lesions at 24 weeks
compared to placebo.
Regeneron and Sanofi said prurigo nodularis is the sixth disease
where Dupixent has shown positive Phase 3 results, adding that they
plan to begin regulatory submissions next year.
Regeneron, of Tarrytown, N.Y., created Dupixent and markets it
jointly in the U.S. with France's Sanofi under a 2007 collaboration
agreement. Sanofi markets the product internationally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 22, 2021 06:24 ET (10:24 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024
